IP Library › Granted Patent US 12,239,678
Granted Patent B2
US 12,239,678 · App. 17/766,959 · Granted Mar 4, 2025

Yeast for the treatment of allergy

Inventors: Trevor Archer (Floda, SE); Tomas Lenz (Örebro, SE)
Assignee: MILMED UNICO AB
A61K36/064A61P37/08C12N1/20C12N13/00C12R2001/86C12R2001/865
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,678
App. No.
17/766,959
Granted
Mar 4, 2025
Kind
B2
Abstract

A yeast cell for use in the treatment and/or alleviation of allergy and/or symptoms caused by allergy, wherein the yeast cell has been treated with electromagnetic waves in the range of 1 GHz to 300 GHz, or said yeast cell has been grown from a yeast cell treated with electromagnetic waves in the range of 1 GHz to 300 GHz, and composition comprising such a yeast cell.

Claims (19)

1. A method of treatment and/or alleviation of allergy and/or symptoms caused by allergy, comprising administering to a subject in need thereof, a yeast cell, wherein the yeast cell has been treated with electromagnetic waves in the range of 1 GHz to 300 GHz, or said yeast cell has been grown from a yeast cell treated with electromagnetic waves in the range of 1 GHz to 300 GHz, thereby treating and/or alleviating allergy and/or symptoms caused by allergy in the subject.

2. The method according to claim 1 , wherein the allergy is selected from the group consisting of allergic rhinitis, mite allergy, fur allergy, seasonal allergy, food allergy.

3. The method according to claim 1 , wherein the allergy is caused by an allergen selected from the group consisting of mite, pollen, animal hair, and animal dander.

4. The method according to claim 1 , wherein said electromagnetic waves are in the range from about 1 GHz to about 200 GHz.

5. The method according to claim 4 , wherein said electromagnetic waves are chosen from group consisting of: 40 GHZ, 41 GHZ, 42 GHZ, 43 GHZ, 44 GHz, 45 GHz, 46 GHZ, 47 GHz, 48 GHZ, 49 GHz, 50 GHZ, 51 GHZ, 52 GHZ, 53 GHZ, 54 GHZ, 55 GHZ, 56 GHZ, 57 GHz, 58 GHZ, 59 GHz, 60 GHz, 61 GHz, 62 GHz, 63 GHz, 64 GHz and 65 GHz.

6. The method according to claim 1 , wherein said electromagnetic waves have a power density below 1 mW/cm 2 .

7. The method according to claim 1 , wherein said electromagnetic waves are modulated in a frequency within the range of 0.01% to about 0.5% of the average frequency.

8. The method according to claim 1 , wherein said yeast cell has been treated with electromagnetic waves for a time period of from 10 minutes to 240 minutes.

9. The method according to claim 1 , wherein said yeast cell is of the genus Saccharomyces.

10. The method according to claim 1 , wherein said electromagnetic waves are in the range from 40 to 65 GHz.

11. The method according to claim 1 , wherein said electromagnetic waves have a power density of between 0.004 mW/cm2 and 0.2 mW/cm2.

12. The method according to claim 1 , wherein said yeast cell has been treated with electromagnetic waves for a time period of from 20 minutes to 120 minutes.

13. The method according to claim 1 , wherein said yeast cell is selected from the group consisting of Saccharomyces carlsbergensis or Saccharomyces cerevisiae.

14. The method according to claim 1 , wherein the yeast cell is present in a composition further comprising an excipient and/or a carrier.

15. The method according to claim 14 , wherein the composition is for oral intake.

16. The method according to claim 14 , wherein the composition is a liquid composition.

17. The method according to claim 16 , wherein the composition comprises the yeast cell in an amount of from 10×10 6 CFUs/mL to 50×10 6 CFUs/mL.

18. The method according to claim 14 , wherein the composition is a powder composition.

19. The method according to claim 16 , wherein the composition comprises the yeast cell in an amount of from 20×10 6 CFUs/mL to 40×10 6 CFUs/mL.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2022
From: ARCHER, TREVOR; LENZ, TOMAS
To: MILMED UNICO AB
Reel/Frame 060840/0106 →
Priority Claims (1)
SE 1951142-7 · Oct 7, 2019 · national
Continuity (1)
Related Publication 20240066083A1 · Feb 29, 2024
References Cited (26)
US 20040001860A1 · Cheung · 2004 [cited by applicant]
US 20040005680A1 · Cheung · 2004 [cited by applicant]
JP 200568092A · 2005 [cited by applicant]
JP 2005104943A · 2005 [cited by applicant]
JP 2008182900A · 2008 [cited by applicant]
JP 2010209015A · 2010 [cited by applicant]
JP 4712289B2 · 2011 [cited by applicant]
JP 2013503138A · 2013 [cited by applicant]
JP 2013247939A · 2013 [cited by applicant]
JP 6002452B2 · 2016 [cited by applicant]
KR 101898508B1 · 2018 [cited by applicant]
WO 2004108919A1 · 2004 [cited by applicant]
WO 2011023769A1 · 2011 [cited by applicant]
Moyad MA, Robinson LE, Kittelsrud JM, Reeves SG, Weaver SE, Guzman AI, Bubak ME. Adv Ther. Aug. 2009;26(8):795-804. doi: 10.1007/s12325-009-0057-y. Epub Aug. 12, 2009. Erratum in: Adv Ther. Aug. 2019;36(8):2191. PMID: 1… [cited by examiner]
Moyad MA, Robinson LE, Zawada ET, Kittelsrud J, Chen DG, Reeves SG, Weaver S. Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals. J Altern Complement Med. Feb. 2010;16(2):213-8. d… [cited by examiner]
Bower et al., Neurology, 2006, vol. 67, p. 494-496. (Year: 2006). [cited by examiner]
Luciano Furia et al: “Effect of Millimeter-Wave Irradiation on Growth of [cited by applicant]
Andrei G Pakhomov A et al: “Low-Intensity Millimeter Waves as a Novel Therapeutic Modality”, IEEE Transactions on Plasma Science, IEEE Service Center, Piscataway, NJ, US, vol. 28, No. 1, Jan. 1, 2000 (Jan. 1, 2000), XP0… [cited by applicant]
Trevor Archer et al: “Milmed Treatment Alleviates Symptoms of Allergy and Improves General Health”, Journal of Immunology and Allergy, vol. 1, No. 3, Jun. 11, 2020 (Jun. 11, 2020) , pp. 3-11, XP093101064, DOI: 10.37191/… [cited by applicant]
Trevor Archer et al: “Amelioration For Allergic Rhinitis and Asthma: The Treated Yeast Milmed and Physical Exercise”, Journal of Immunology and Allergy, vol. 1, No. 1, Nov. 19, 2019 (Nov. 19, 2019), pp. 1-6, XP093101165… [cited by applicant]
Erixon RM, et al., Amelioration For Allergic Rhinitis and Asthma: The Treated Yeast Milmed and Physical Exercise, J Immuno Allerg. Published Nov. 19, 2019. [cited by applicant]
Fonseca VMB, Milani TMS, Prado R, Bonato VLD, Ramos SG, Martins FS, Vianna EO, Borges MC. Oral administration of [cited by applicant]
Yeh CY, Jung CJ, Huang CN, Huang YC, Lien HT, Wang WB, Wang LF, Chia JS. A legume product fermented by [cited by applicant]
Archer T, Fredriksson A. The yeast product Milmed enhances the effect of physical exercise on motor performance and dopamine neurochemistry recovery in MPTP-lesioned mice. Neurotox Res. Oct. 2013;24(3):393-406. doi: 10.… [cited by applicant]
Archer T. et al., ‘Mil med Treatment Alleviated or Abolished Allergy’, J Immuno Allerg. Mar. 2, 2020, vol. 1, pp. 1-13; whole document. [cited by applicant]
International Search Report corresponding to Application No. PCT/SE2020/050958 mailed Oct. 21, 2020. [cited by applicant]